Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Viral Infections

Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation


Hepatitis B virus/hepatitis C virus (HBV/HCV) positive patients undergoing haemopoietic stem cell transplantation (HSCT) are at risk of hepatitis reactivation and fatal liver failure: we have conducted a retrospective study to assess the risk in 20 Italian transplant centres. A total of 90 patients infected with HBV (n=33) or HCV (n=57) receiving allogeneic (n=36) or autologous (n=54) haemotopoietic stem cell transplant (HSCT) between 1996 and 2000 were reviewed. The biochemical profiles and outcomes of infection-related liver disease were also analysed. The risk of death at 2 years was comparable when considering type of infection (3% for HBV vs 8% for HCV, P=0.6) or type of HSCT (7% for allogeneic vs 5% for autologous HHSCT, P=0.34). Hepatitis reactivation followed by resolution was more frequent in HCV+ than in HBV+ patients receiving an allograft (100% vs 16%, P=0.004). In HBV+ cases, risk of reactivation was comparable after autologous or allogeneic transplantation (66 vs 81%, P=0.3), but liver disease was more severe and occurred earlier in the autologous group. Our results indicate that HBV and HCV infection should not be taken as an absolute contraindication for HSCT and the risk of life-threatening liver complications are similar after allogeneic or autologous transplants.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others


  1. Locasciulli A et al. The role of hepatitis C and B virus infection as Risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation 1999; 68: 1486–1491.

    Article  CAS  Google Scholar 

  2. Locasciulli A et al. Impact of liver disease and hepatitis infections on allogeneic bone marrow transplantation in Europe: a survey from the European Bone marrow Transplantation (EBMT) Group—Infectious Diseases Working Party. Bone Marrow Transplant 1994; 14: 833–837.

    CAS  PubMed  Google Scholar 

  3. McDonald GB, Shulman HM, Spencer GD . Liver disease after human marrow transplant. Semin Liv Dis 1987; 7: 210–229.

    Article  CAS  Google Scholar 

  4. Azar N et al. Liver dysfunction in allogeneic bone marrow transplantation recipients. Transplantation 1996; 62: 56–61.

    Article  CAS  Google Scholar 

  5. Pariente EA et al. Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogeneic bone marrow transplantation. Dig Dis Sci 1988; 33: 1185–1191.

    Article  CAS  Google Scholar 

  6. Frickhofen N et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994; 83: 1998–2004.

    CAS  PubMed  Google Scholar 

  7. Kolho E, Ruutu P, Ruutu T . Hepatitis C infection in BMT patients. Bone Marrow Transplant 1993; 11: 119–123.

    CAS  PubMed  Google Scholar 

  8. Fujii Y et al. Hepatitis C virus infection and liver disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 13: 523–526.

    CAS  PubMed  Google Scholar 

  9. Rodriguez-Inigo E et al. Hepatitis C and G virus infection and liver dysfunction after allogeneic bone marrow transplantation: results from a prospective study. Blood 1997; 90: 1326–1331.

    CAS  PubMed  Google Scholar 

  10. Locasciulli A et al. Morbidity and mortality due to liver disease in children undergoing allogeneic bone marrow transplantation: a 10-year prospective study. Blood 1997; 90: 3799–3805.

    CAS  Google Scholar 

  11. McDonald GB et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255–267.

    Article  CAS  Google Scholar 

  12. Storb R et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.

    Article  CAS  Google Scholar 

  13. Bernuau J, Rueff B, Benhamou JP . Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis 1986; 6: 97–106.

    Article  CAS  Google Scholar 

  14. Locasciulli A et al. Hepatitis C virus infection and liver failure in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 16: 407–411.

    CAS  PubMed  Google Scholar 

  15. Picardi M et al. Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 21: 1267–1269.

    Article  CAS  Google Scholar 

  16. Uchida N et al. Lamivudine therapy for a hepatitis B surface antigen (HbsAg)-positive leukaemia patient receiving myeloablative chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 2000; 26: 1243–1245.

    Article  CAS  Google Scholar 

  17. Persico M et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002; 99: 724–725.

    Article  CAS  Google Scholar 

Download references


We are grateful to the following GITMO Members and Centres contributing patients to the Study: (1) G Meloni, G Arcese, Dip. Biol cellulari e Ematologia, Univ ‘La Sapienza’ Roma; (2) I Majolino, Div. Ematologia e TMO, Osp. San Camillo, Roma; (3) G De Rosa, C Selleri Div. Ematologia, Univ. ‘Federico II’, Napoli, (4) S Cesaro, Clinica Oncoematologia Pediatrica e Centro Leucemie Infantili, Padova; (5) EP Alessandrino, Dip. Ematologia e TMO, Policlinico S Matteo, Pavia; (6) C Cesana, Istituto Clinico Humanitas, Rozzano, Milano; (7) V Cassibba, Ematologia e TMO, Osp. Generale Regionale Bolzano; (8) IM Liberati, Med. Int e Scienze Oncologiche, Policlinico Monteluce, Perugia; (9) A Palmas, Div. Ematologia Osp. S Francesco, Nuoro; (10) L Tasso, Div. Malattie Infettive, Ist. G Gaslini, Genova; (11) F Narni, Sez. Emato-Oncologia, Univ. Modena; (12) E Pogliani, Ematologia, Osp. S Gerardo, Univ. Milano-Bicocca, Monza (Mi); (13) A Rovelli, Emat. Pediatrica e TMO, Osp. S. Gerardo, Univ. Milano-Bicocca, Monza (Mi) (14) E Morra, P Marenco, Ematologia e TMO, Osp. Niguarda, Milano; (15) A Bacigalupo, Dip. Ematologia, Osp. S Martino, Genova; (16) R Raimondi, div. Ematologia, Osp. S Bartolo, Vicenza; (17) C Bergonzi, Sez. Ematologia e TMO, Medicina II, Cremona; (18) G Irrera, Osp. ‘Bianchi-Melacrino-Morelli’, Reggio Calabria; (19) S Ceppi, Oncoematologia Pediatrica, Osp. Silvestrini, Perugia; (20) G Bandini, Ist. Ematologia ‘Seragnoli’, Osp. S. Orsola, Bologna. Partially supported by a grant of AIRC (Associazione Italiana Ricerca Cancro).

Author information

Authors and Affiliations


Rights and permissions

Reprints and permissions

About this article

Cite this article

Locasciulli, A., Bruno, B., Alessandrino, E. et al. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant 31, 295–300 (2003).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:



Quick links